Utilization of Hepatitis B Virus NAT+ Donors for Hepatitis B Vaccinated Lung Transplant Candidates
Status:
Not yet recruiting
Trial end date:
2032-08-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to determine the safety and efficacy of transplanting lungs
from hepatitis B virus (HBV) nucleic acid test positive (NAT+) donors into HBV vaccinated HBV
surface antibody positive (sAb+) lung transplant candidates, who will then be treated with
Hepatitis B Immune Globulin (HBIG) and entecavir, tenofovir disoproxil, or tenofovir
alafenamide.